李瑜铭

【摘要】目的 探讨曲美他嗪联合阿托伐他汀治疗冠心病的效果及其对患者血脂与血液流变学的影响。方法 此次选择了2015年1月～2016年8月于我院诊治的冠心病患者80例作为研究对象，将患者根据其治疗方式分为两组（对照组、观察组）进行实验，为对照组40例患者单纯以阿托伐他汀治疗，而为观察组40例患者用曲美他嗪+阿托伐他汀治疗。结果 观察组治疗效果优于对照组；观察组患者血脂指标优于对照组；观察组患者血液流变学指标低于对照组；上述组间比较差异有统计学意义（P<0.05）。结论 用曲美他嗪+阿托伐他汀治疗冠心病患者的效果显著，用药后可有效调节血脂，促使血液流变学水平恢复正常。

【关键词】曲美他嗪；阿托伐他汀；血脂

【中图分类号】R541.4 【文 献标识码】A 【文章编号】ISSN.2095-6681.2016.36.00.02

The effect of trimetazidine combined with atorvastatin on coronary heart disease and its influence on blood lipid and Hemorheology

LI Yu-ming

（Sichuan province Quxian County Qing Town Central Health Center，Sichuan Dazhou 635222，China）

【Abstract 】Objective To study the trimetazidine joint atorvastatin for treatment of coronary heart disease（CHD）and its effect on the patient's blood lipid and blood rheology.Methods The selected in January 2015-December 2016 in our hospital make a diagnosis and give treatment of 80 patients with coronary heart disease（CHD）as the research object，the patients into two groups according to their treatments （control group and observation group）experiment，for control group 40 cases with simple treatment with atorvastatin，and to observe group of 40 patients with trimetazidine + atorvastatin treatment.Results To observe the clinical therapeutic effect is better than the control group；Observation group of patients with blood lipid index is better than the control group；Observation group the indexes of blood rheology in patients with lower than control group；Comparative differences between the groups was statistically significant（P<0.05）.Conclusion With trimetazidine+atorvastatin therapy in patients with coronary heart disease in clinical effect is remarkable，after can regulate blood lipid，hemorheology level back to normal.

【Key words】Trimetazidine；Atorvastatin；Blood lipid

臨床上用来治疗冠心病的药物诸多，但各种药物的有效性、安全性均是不同的。此次将所选患者80例根据其治疗方式分为两组进行实验，对照组患者单纯用阿托伐他汀治疗，观察组用用曲美他嗪+阿托伐他汀治疗，探讨了曲美他嗪联合阿托伐他汀治疗冠心病的疗效及对患者血脂和血液流变学的影响，现将报道如下。

1 资料与方法

1.1 一般资料

将所选患者80例根据其治疗方式分为对照组与观察组进行实验：对照组40例男28例、女12例；年龄46～81岁，平均年龄为（62.09±10.74）岁。观察组40例男26例、女14例；年龄47～80岁，平均年龄为（61.85±10.31）岁；两组患者一般资料比较，差异无统计学意义（P>0.05）。

1.2 方法

1.2.1 对照组方法

为对照组患者单纯以阿托伐他汀治疗，给予患者常规吸氧、利尿剂、硝酸盐、扩血管药、β-受体阻滞剂、钙拮抗剂等方面基础治疗后[1]，让患者服用阿托伐他汀，1次10 mg、1天1次；……